Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Encephalitis, Tick-Borne

ClinicalTrials.gov lists 50 trials for Encephalitis, Tick-Borne or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 19.

MeSH D004675 Infections C01 C10 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 2 Phase 2 7 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 7 Phase 4 Phase 4 16 Not applicable Not applicable 3 Observational Observational 12 Phase 1 Phase 1 2 Phase 2 Phase 2 7 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 7 Phase 4 Phase 4 16 Not applicable Not applicable 3 Observational Observational 12

Trials per phase

50 of the 50 trials are tagged with Encephalitis, Tick-Borne itself; the rest are tagged with a narrower condition beneath it.

Get the Encephalitis, Tick-Borne report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Encephalitis, Tick-Borne trials start? (21)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 5

1998: 1 trials (Phase 2/3 1) 2001: 2 trials (Phase 3 1, Phase 2 1) 2002: 5 trials (Phase 3 2, Phase 2 3) 2004: 2 trials (Phase 4 2) 2005: 5 trials (Observational 1, Phase 4 3, Phase 1 1) 2006: 2 trials (Phase 4 1, Phase 3 1) 2007: 4 trials (Observational 1, Phase 4 2, Phase 2 1) 2008: 1 trials (Phase 4 1) 2009: 5 trials (Observational 1, Phase 4 2, Phase 3 1, Phase 2 1) 2011: 1 trials (Phase 2/3 1) 2012: 3 trials (Phase 4 3) 2014: 4 trials (Observational 1, Not applicable 2, Phase 2 1) 2015: 2 trials (Phase 4 1, Phase 2/3 1) 2019: 1 trials (Observational 1) 2020: 1 trials (Observational 1) 2021: 1 trials (Phase 3 1) 2022: 2 trials (Observational 2) 2023: 2 trials (Observational 2) 2024: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 2025: 2 trials (Observational 1, Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 2
2024 3
2023 2
2022 2
2021 1
2020 1
2019 1
2015 2
2014 4

Showing 10 of 21 earlier years.

Start your 14-day trial Email me all 21 earlier years as a PDF

No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 50 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Encephalitis, Tick-Borne trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 2 7
Phase 2/3 3
Phase 3 7
Phase 4 16
Not applicable 3
Observational 12

How many Encephalitis, Tick-Borne trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 2
Recruiting 5
Active, not recruiting 1
Completed 33
Terminated 1

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Encephalitis, Tick-Borne trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 19
Novartis 3
National Institute of Allergy and Infectious Diseases (NIAID) 2
GlaxoSmithKline 1
Novartis Vaccines 1

Interventions as named in the registry (15)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) 13
Symptomatic therapy 3
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl 3
FSME-immune 2
FSME-IMMUN Vaccine 2

Showing 5 of 15 interventions.

Start your 14-day trial Email me all 15 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Encephalitis, Tick-Borne trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
ADENOIDAL DISORDER 2 1
ADENOIDAL HYPERTROPHY 2 1
BRONCHITIS 2 1
Urinary tract infection, relapsing fever 2 1
ACQUIRED PHIMOSIS 1 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Encephalitis, Tick-Borne? (32)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older. Vaccine 2024 Yes
Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up. Vaccine 2023 Yes
Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50 years or older: A single-centre, open-label, randomized controlled trial. Vaccine 2022 Yes
Tick-borne Encephalitis Vaccine Failures: A 10-year Retrospective Study Supporting the Rationale for Adding an Extra Priming Dose in Individuals Starting at Age 50 Years. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Yes
Tick-borne encephalitis vaccination in multiple sclerosis: A prospective, multicenter study. Neurology(R) neuroimmunology & neuroinflammation 2020 Yes

Showing 5 of 32 publications.

Start your 14-day trial Email me all 32 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Tick-borne encephalitis Point prevalence Unknown Worldwide Not stated Unspecified
Tick-borne encephalitis Point prevalence Unknown Worldwide Not stated Exact
Tick-borne encephalitis Point prevalence Unknown Worldwide Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Tick-borne encephalitis 297 Exact Orphadata Science knowledge files, Product 1
Tick-borne encephalitis 297 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages